{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:58Z","timestamp":1792787878817,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University Industrial Technology Force","award":["0720142100"],"award-info":[{"award-number":["0720142100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Helicobacter pylori (\n                      <jats:italic>H. pylori<\/jats:italic>\n                      ) is an important pathogen that causes chronic gastritis and peptic ulcer, and is related to the development of gastric carcinoma. Several chemicals, including antibiotics, have been used to eradicate\n                      <jats:italic>H.pylori<\/jats:italic>\n                      . However, more studies are yet requred to accomplish a sufficient therapy.\n                      <jats:italic>Pediococcus acidilactici<\/jats:italic>\n                      (\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      ) J9 were studied for inhibition of binding of\n                      <jats:italic>H.pylori<\/jats:italic>\n                      binding to human gastric cell lines. This study was performed in order to investigate the repeated-dose toxicity of\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9 in male and female mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      C57BL\/6 male and female\n                      <jats:italic>Mus musculus<\/jats:italic>\n                      were divided into four groups (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910 in each group).\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9 was administered daily by oral injection of vehicle control at dosage levels to a low-dose group (500\u2009mg\/kg\/day), middle-dose group (1000\u2009mg\/kg\/day), and high-dose group (2000\u2009mg\/kg\/day) for 2 weeks. After 14\u2009days of exposure, the blood biochemistry and hematology were investigated, along with a histopathology exam. There were no bacterial-related deaths or abnormal clinical signs in either gender of mouse. The data was observed during the period in terms of body weight, food intake, and water consumption. Also, no alterations in organ weights upon administration of\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9 alone were observed. The adhesion and growth of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      were inhibited by a 24\u2009h treatment of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      and\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9 on adenocarcinoma gastric (AGS) cells, which are gastric cancer cells. Compared to the control group (AGS cell and\n                      <jats:italic>H. pylori<\/jats:italic>\n                      ), the number of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      analyzed by FACS significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) decreased after incubation of AGS cell with\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9 for 24\u2009h.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These results suggest that the oral application of\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9, up to a dosage level of 2000\u2009mg\/kg\/day, causes no adverse effects in both male and female mice.\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9 inhibits the adhesion of\n                      <jats:italic>H.pylori<\/jats:italic>\n                      to AGS cancer cells. When used as probiotics,\n                      <jats:italic>P. acidilactici<\/jats:italic>\n                      J9 may help decrease the occurrence of gastritis and reduce the risk of\n                      <jats:italic>H.pylori<\/jats:italic>\n                      infection with promising safety issues.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12866-020-02055-4","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T08:21:59Z","timestamp":1607502119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model"],"prefix":"10.1186","volume":"20","author":[{"given":"Mijung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Yeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooseok","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"issue":"2","key":"2055_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.femsim.2004.04.001","volume":"42","author":"ML Cross","year":"2004","unstructured":"Cross ML, Ganner A, Teilab D, Fray LM. Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria. FEMS Immunol Med Microbiol. 2004;42(2):173\u201380. https:\/\/doi.org\/10.1016\/j.femsim.2004.04.001.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"2","key":"2055_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1128\/MR.59.2.171-200.1995","volume":"59","author":"RW Jack","year":"1995","unstructured":"Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. Microbiol Rev. 1995;59(2):171\u2013200.","journal-title":"Microbiol Rev"},{"issue":"4","key":"2055_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000104752","volume":"13","author":"L De Vuyst","year":"2007","unstructured":"De Vuyst L, Leroy F. Bacteriocins from lactic acid bacteria: production, purification, and food applications. J Mol Microbiol Biotechnol. 2007;13(4):194\u20139. https:\/\/doi.org\/10.1159\/000104752.","journal-title":"J Mol Microbiol Biotechnol"},{"issue":"1","key":"2055_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0147-619X(89)90082-6","volume":"21","author":"K Josson","year":"1989","unstructured":"Josson K, Scheirlinck T, Michiels F, Platteeuw C, Stanssens P, Joos H, et al. Characterization of a gram-positive broad-host-range plasmid isolated from Lactobacillus hilgardii. Plasmid. 1989;21(1):9\u201320.","journal-title":"Plasmid."},{"issue":"8 Suppl","key":"2055_CR5","first-page":"S116","volume":"89","author":"BJ Marshall","year":"1994","unstructured":"Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89(8 Suppl):S116\u201328.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2055_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0016-5085(99)70119-8","volume":"116","author":"T Lind","year":"1999","unstructured":"Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999;116(2):248\u201353.","journal-title":"Gastroenterology."},{"issue":"1","key":"2055_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1128\/JCM.38.1.210-214.2000","volume":"38","author":"S Maeda","year":"2000","unstructured":"Maeda S, Yoshida H, Matsunaga H, Ogura K, Kawamata O, Shiratori Y, et al. Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol. 2000;38(1):210\u20134.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"2055_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/gut.43.3.317","volume":"43","author":"S Maeda","year":"1998","unstructured":"Maeda S, Yoshida H, Ogura K, Kanai F, Shiratori Y, Omata M. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut. 1998;43(3):317\u201321.","journal-title":"Gut."},{"issue":"11","key":"2055_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/j.1572-0241.1998.00600.x","volume":"93","author":"Y Aiba","year":"1998","unstructured":"Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acid-mediated suppression of helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol. 1998;93(11):2097\u2013101. https:\/\/doi.org\/10.1111\/j.1572-0241.1998.00600.x.","journal-title":"Am J Gastroenterol"},{"issue":"45","key":"2055_CR10","doi-asserted-by":"publisher","first-page":"8168","DOI":"10.3748\/wjg.v19.i45.8168","volume":"19","author":"E Ierardi","year":"2013","unstructured":"Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change helicobacter pylori treatment: a matter of geography? World J Gastroenterol. 2013;19(45):8168\u201380. https:\/\/doi.org\/10.3748\/wjg.v19.i45.8168.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2055_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/MEG.0b013e32830d0eff","volume":"21","author":"A Sachdeva","year":"2009","unstructured":"Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2009;21(1):45\u201353. https:\/\/doi.org\/10.1097\/MEG.0b013e32830d0eff.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"2055_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1523-5378.2012.00992.x","volume":"17","author":"PS Hsieh","year":"2012","unstructured":"Hsieh PS, Tsai YC, Chen YC, Teh SF, Ou CM, King VA. Eradication of helicobacter pylori infection by the probiotic strains Lactobacillus johnsonii MH-68 and L. salivarius ssp. salicinius AP-32. Helicobacter. 2012;17(6):466\u201377. https:\/\/doi.org\/10.1111\/j.1523-5378.2012.00992.x.","journal-title":"Helicobacter."},{"issue":"12","key":"2055_CR13","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1086\/430318","volume":"191","author":"KC Johnson-Henry","year":"2005","unstructured":"Johnson-Henry KC, Nadjafi M, Avitzur Y, Mitchell DJ, Ngan BY, Galindo-Mata E, et al. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis. 2005;191(12):2106\u201317. https:\/\/doi.org\/10.1086\/430318.","journal-title":"J Infect Dis"},{"issue":"2","key":"2055_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.176.2.1228","volume":"176","author":"MT Tien","year":"2006","unstructured":"Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppee JY, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol. 2006;176(2):1228\u201337.","journal-title":"J Immunol"},{"issue":"3","key":"2055_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1046\/j.1365-2672.2003.01850.x","volume":"94","author":"MF Fernandez","year":"2003","unstructured":"Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol. 2003;94(3):449\u201355.","journal-title":"J Appl Microbiol"},{"issue":"2","key":"2055_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1523-5378.2009.00743.x","volume":"15","author":"E Lionetti","year":"2010","unstructured":"Lionetti E, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R. Role of probiotics in pediatric patients with helicobacter pylori infection: a comprehensive review of the literature. Helicobacter. 2010;15(2):79\u201387. https:\/\/doi.org\/10.1111\/j.1523-5378.2009.00743.x.","journal-title":"Helicobacter."},{"issue":"1","key":"2055_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1574-6968.2006.00250.x","volume":"259","author":"SC De Keersmaecker","year":"2006","unstructured":"De Keersmaecker SC, Verhoeven TL, Desair J, Marchal K, Vanderleyden J, Nagy I. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett. 2006;259(1):89\u201396. https:\/\/doi.org\/10.1111\/j.1574-6968.2006.00250.x.","journal-title":"FEMS Microbiol Lett"},{"issue":"1","key":"2055_CR18","first-page":"44","volume":"21","author":"RB Sartor","year":"2005","unstructured":"Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005;21(1):44\u201350.","journal-title":"Curr Opin Gastroenterol"},{"issue":"4 Pt 1","key":"2055_CR19","first-page":"G941","volume":"276","author":"DR Mack","year":"1999","unstructured":"Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Phys. 1999;276(4 Pt 1):G941\u201350.","journal-title":"Am J Phys"},{"issue":"11","key":"2055_CR20","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1128\/AEM.64.11.4573-4580.1998","volume":"64","author":"MH Coconnier","year":"1998","unstructured":"Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 1998;64(11):4573\u201380.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"2055_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.6114\/jkood.2020.33.1.025","volume":"33","author":"S-J Hong","year":"2020","unstructured":"Hong S-J, Chong M-S, Ahn S-H. A review on effects of probiotics in atopic dermatitis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2020;33(1):25\u201344. https:\/\/doi.org\/10.6114\/jkood.2020.33.1.025.","journal-title":"J Korean Med Ophthalmol Otolaryngol Dermatol"},{"issue":"4","key":"2055_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2672.1988.tb01893.x","volume":"65","author":"AK Bhunia","year":"1988","unstructured":"Bhunia AK, Johnson MC, Ray B. Purification, characterization and antimicrobial spectrum of a bacteriocin produced by Pediococcus acidilactici. J Appl Bacteriol. 1988;65(4):261\u20138. https:\/\/doi.org\/10.1111\/j.1365-2672.1988.tb01893.x.","journal-title":"J Appl Bacteriol"},{"key":"2055_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1590\/S1516-8913201402258","volume":"57","author":"MCO Ribeiro","year":"2014","unstructured":"Ribeiro MCO, Vandenberghe LPS, Spier MR, Paludo KS, Soccol CR, Soccol VT. Evaluation of probiotic properties of Pediococcus acidilactici B14 in association with Lactobacillus acidophilus ATCC 4356 for application in a soy based aerated symbiotic dessert. Braz Arch Biol Technol. 2014;57:755\u201365.","journal-title":"Braz Arch Biol Technol"},{"issue":"5","key":"2055_CR24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/ijfs.12768","volume":"50","author":"J Barbosa","year":"2015","unstructured":"Barbosa J, Borges S, Teixeira P. Pediococcus acidilactici as a potential probiotic to be used in food industry. Int J Food Sci Technol. 2015;50(5):1151\u20137. https:\/\/doi.org\/10.1111\/ijfs.12768.","journal-title":"Int J Food Sci Technol"},{"issue":"5","key":"2055_CR25","doi-asserted-by":"publisher","first-page":"e12529","DOI":"10.1111\/hel.12529","volume":"23","author":"AG McNicholl","year":"2018","unstructured":"McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, P\u00e9rez-Aisa \u00c1, Modolell I, et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529. https:\/\/doi.org\/10.1111\/hel.12529.","journal-title":"Helicobacter"},{"key":"2055_CR26","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.3389\/fmicb.2019.02770","volume":"10","author":"F Zuo","year":"2019","unstructured":"Zuo F, Appaswamy A, Gebremariam HG, Jonsson AB. Role of Sortase A in lactobacillus gasseri Kx110A1 adhesion to gastric epithelial cells and competitive exclusion of helicobacter pylori. Front Microbiol. 2019;10:2770. https:\/\/doi.org\/10.3389\/fmicb.2019.02770.","journal-title":"Front Microbiol"},{"issue":"3","key":"2055_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.22270\/jddt.v10i3.4055","volume":"10","author":"R Belhattab","year":"2020","unstructured":"Belhattab R, Merouani N. Acute toxicity of Aristolochia longa L. of aqueous extract in mice. J Drug Deliv Ther. 2020;10(3):4\u201310. https:\/\/doi.org\/10.22270\/jddt.v10i3.4055.","journal-title":"J Drug Deliv Ther"},{"issue":"13","key":"2055_CR28","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1016\/j.biortech.2007.11.015","volume":"99","author":"S Anastasiadou","year":"2008","unstructured":"Anastasiadou S, Papagianni M, Filiousis G, Ambrosiadis I, Koidis P. Pediocin SA-1, an antimicrobial peptide from Pediococcus acidilactici NRRL B5627: Production conditions, purification and characterization. Bioresour Technol. 2008;99(13):5384\u201390. https:\/\/doi.org\/10.1016\/j.biortech.2007.11.015.","journal-title":"Bioresour Technol"},{"issue":"2","key":"2055_CR29","first-page":"310","volume":"28","author":"S Stonsaovapak","year":"1994","unstructured":"Stonsaovapak S, Kaneko J, Izaki K. Characterization of Bacteriocin Produced by Pediococcus acidilactici Isolated from Fermented Pork in Thailand. Agric Nat Resour. 1994;28(2):310\u20133.","journal-title":"Agric Nat Resour"},{"issue":"1","key":"2055_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2672.1991.tb03782.x","volume":"70","author":"AK Bhunia","year":"1991","unstructured":"Bhunia AK, Johnson MC, Ray B, Kalchayanand N. Mode of action of pediocin AcH from Pediococcus acidilactici H on sensitive bacterial strains. J Appl Bacteriol. 1991;70(1):25\u201333. https:\/\/doi.org\/10.1111\/j.1365-2672.1991.tb03782.x.","journal-title":"J Appl Bacteriol"},{"issue":"4","key":"2055_CR31","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1128\/AEM.57.4.1265-1267.1991","volume":"57","author":"SR Biswas","year":"1991","unstructured":"Biswas SR, Ray P, Johnson MC, Ray B. Influence of growth conditions on the production of a Bacteriocin, Pediocin AcH, by Pediococcus acidilactici H. Appl Environ Microbiol. 1991;57(4):1265\u20137.","journal-title":"Appl Environ Microbiol"},{"issue":"9","key":"2055_CR32","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1128\/AEM.60.9.3405-3408.1994","volume":"60","author":"M Bukhtiyarova","year":"1994","unstructured":"Bukhtiyarova M, Yang R, Ray B. Analysis of the pediocin AcH gene cluster from plasmid pSMB74 and its expression in a pediocin-negative Pediococcus acidilactici strain. Appl Environ Microbiol. 1994;60(9):3405.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"2055_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijfoodmicro.2004.10.040","volume":"101","author":"R Bauer","year":"2005","unstructured":"Bauer R, Chikindas ML, Dicks LMT. Purification, partial amino acid sequence and mode of action of pediocin PD-1, a bacteriocin produced by Pediococcus damnosus NCFB 1832. Int J Food Microbiol. 2005;101(1):17\u201327. https:\/\/doi.org\/10.1016\/j.ijfoodmicro.2004.10.040.","journal-title":"Int J Food Microbiol"},{"issue":"3","key":"2055_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/18722083113076660008","volume":"7","author":"R Mehta","year":"2013","unstructured":"Mehta R, Arya R, Goyal K, Singh M, K. Sharma A. Bio-preservative and therapeutic potential of Pediocin: recent trends and future perspectives. Recent Pat Biotechnol. 2013;7(3):172\u20138.","journal-title":"Recent Pat Biotechnol"},{"issue":"3","key":"2055_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/18722083113076660008","volume":"7","author":"R Mehta","year":"2013","unstructured":"Mehta R, Arya R, Goyal K, Singh M, Sharma AK. Bio-preservative and therapeutic potential of pediocin: recent trends and future perspectives. Recent Pat Biotechnol. 2013;7(3):172\u20138.","journal-title":"Recent Pat Biotechnol"},{"issue":"1","key":"2055_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2672.1997.00241.x","volume":"83","author":"G Green","year":"1997","unstructured":"Green G, Dicks LMT, Bruggeman G, Vandamme EJ, Chikindas ML. Pediocin PD-1, a bactericidal antimicrobial peptide from Pediococcus damnosus NCFB 1832. J Appl Microbiol. 1997;83(1):127\u201332. https:\/\/doi.org\/10.1046\/j.1365-2672.1997.00241.x.","journal-title":"J Appl Microbiol"},{"issue":"19","key":"2055_CR37","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1021\/acs.biochem.5b00164","volume":"54","author":"C Oppeg\u00e5rd","year":"2015","unstructured":"Oppeg\u00e5rd C, Fimland G, Anonsen JH, Nissen-Meyer J. The Pediocin PA-1 accessory protein ensures correct disulfide bond formation in the antimicrobial peptide Pediocin PA-1. Biochemistry. 2015;54(19):2967\u201374. https:\/\/doi.org\/10.1021\/acs.biochem.5b00164.","journal-title":"Biochemistry."},{"issue":"11","key":"2055_CR38","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1128\/aem.66.11.4798-4802.2000","volume":"66","author":"L Johnsen","year":"2000","unstructured":"Johnsen L, Fimland G, Eijsink V, Nissen-Meyer J. Engineering increased stability in the antimicrobial peptide Pediocin PA-1. Appl Environ Microbiol. 2000;66(11):4798\u2013802. https:\/\/doi.org\/10.1128\/aem.66.11.4798-4802.2000.","journal-title":"Appl Environ Microbiol"},{"issue":"12","key":"2055_CR39","first-page":"1716","volume":"87","author":"N Chiba","year":"1992","unstructured":"Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating helicobacter pylori. Am J Gastroenterol. 1992;87(12):1716\u201327.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2055_CR40","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1136\/gut.2003.022111","volume":"53","author":"F M\u00e9graud","year":"2004","unstructured":"M\u00e9graud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374\u201384. https:\/\/doi.org\/10.1136\/gut.2003.022111.","journal-title":"Gut."},{"issue":"4","key":"2055_CR41","first-page":"409","volume":"19","author":"V De Francesco","year":"2010","unstructured":"De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19(4):409\u201314.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5","key":"2055_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/QCO.0000000000000396","volume":"30","author":"C Alba","year":"2017","unstructured":"Alba C, Blanco A, Alarc\u00f3n T. Antibiotic resistance in helicobacter pylori. Curr Opin Infect Dis. 2017;30(5):489\u201397. https:\/\/doi.org\/10.1097\/QCO.0000000000000396.","journal-title":"Curr Opin Infect Dis"},{"key":"2055_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/00365529309098333","volume":"196","author":"P Sipponen","year":"1993","unstructured":"Sipponen P, Hyvarinen H. Role of helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol Suppl. 1993;196:3\u20136.","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"4","key":"2055_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrmicro2319","volume":"8","author":"DI Andersson","year":"2010","unstructured":"Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010;8(4):260\u201371. https:\/\/doi.org\/10.1038\/nrmicro2319.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"2055_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.15403\/jgld.2014.1121.263.zul","volume":"26","author":"A Zullo","year":"2017","unstructured":"Zullo A, De Francesco V, Bellesia A, Vassallo R, D'Angelo A, Scaccianoce G, et al. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice. J Gastrointestin Liver Dis. 2017;26(3):225\u20139. https:\/\/doi.org\/10.15403\/jgld.2014.1121.263.zul.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"2055_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/00365521.2017.1413132","volume":"53","author":"H Li","year":"2018","unstructured":"Li H, Liang X, Chen Q, Zhang W, Lu H. Inappropriate treatment in helicobacter pylori eradication failure: a retrospective study. Scand J Gastroenterol. 2018;53(2):130\u20133. https:\/\/doi.org\/10.1080\/00365521.2017.1413132.","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"2055_CR47","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1007\/s10620-017-4628-5","volume":"62","author":"M Mohammadi","year":"2017","unstructured":"Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an underutilized drug for H. pylori eradication: lessons from Iran. Dig Dis Sci. 2017;62(8):1890\u20136. https:\/\/doi.org\/10.1007\/s10620-017-4628-5.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2055_CR48","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1745-7254.2008.00808.x","volume":"29","author":"YH Kong","year":"2008","unstructured":"Kong YH, Zhang L, Yang ZY, Han C, Hu LH, Jiang HL, et al. Natural product juglone targets three key enzymes from helicobacter pylori: inhibition assay with crystal structure characterization. Acta Pharmacol Sin. 2008;29(7):870\u20136. https:\/\/doi.org\/10.1111\/j.1745-7254.2008.00808.x.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"2055_CR49","doi-asserted-by":"publisher","first-page":"12874","DOI":"10.1038\/s41598-019-49415-3","volume":"9","author":"L Wu","year":"2019","unstructured":"Wu L, Wang Z, Sun G, Peng L, Lu Z, Yan B, et al. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep. 2019;9(1):12874. https:\/\/doi.org\/10.1038\/s41598-019-49415-3.","journal-title":"Sci Rep"},{"issue":"2","key":"2055_CR50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1055\/s-0042-116441","volume":"67","author":"T Kafshdooz","year":"2017","unstructured":"Kafshdooz T, Akbarzadeh A, Majdi Seghinsara A, Pourhassan M, Nasrabadi HT, Milani M. Role of probiotics in managing of helicobacter pylori infection: a review. Drug Res. 2017;67(2):88\u201393. https:\/\/doi.org\/10.1055\/s-0042-116441.","journal-title":"Drug Res"},{"issue":"1","key":"2055_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00253-017-8535-7","volume":"102","author":"K Goderska","year":"2018","unstructured":"Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102(1):1\u20137. https:\/\/doi.org\/10.1007\/s00253-017-8535-7.","journal-title":"Appl Microbiol Biotechnol"},{"key":"2055_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cimid.2019.02.010","volume":"64","author":"M Eslami","year":"2019","unstructured":"Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, et al. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99\u2013108. https:\/\/doi.org\/10.1016\/j.cimid.2019.02.010.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"6","key":"2055_CR53","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1053\/j.gastro.2009.01.072","volume":"136","author":"GA Preidis","year":"2009","unstructured":"Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009;136(6):2015\u201331.","journal-title":"Gastroenterology."},{"issue":"3","key":"2055_CR54","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1053\/gast.2001.27224","volume":"121","author":"K Madsen","year":"2001","unstructured":"Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121(3):580\u201391.","journal-title":"Gastroenterology."},{"issue":"7","key":"2055_CR55","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0167-7799(97)01056-1","volume":"15","author":"GW Tannock","year":"1997","unstructured":"Tannock GW. Probiotic properties of lactic-acid bacteria: plenty of scope for fundamental R & D. Trends Biotechnol. 1997;15(7):270\u20134.","journal-title":"Trends Biotechnol"},{"key":"2055_CR56","doi-asserted-by":"publisher","unstructured":"Dickerson FB, Stallings C, Origoni A, Katsafanas E, Savage CL, Schweinfurth LA, et al. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord. 2014;16(1):PCC.13m01579. https:\/\/doi.org\/10.4088\/PCC.13m01579.","DOI":"10.4088\/PCC.13m01579"},{"issue":"1","key":"2055_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jconrel.2012.06.003","volume":"162","author":"MT Cook","year":"2012","unstructured":"Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 2012;162(1):56\u201367. https:\/\/doi.org\/10.1016\/j.jconrel.2012.06.003.","journal-title":"J Control Release"},{"issue":"52","key":"2055_CR58","doi-asserted-by":"publisher","first-page":"50959","DOI":"10.1074\/jbc.M207050200","volume":"277","author":"F Yan","year":"2002","unstructured":"Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277(52):50959\u201365. https:\/\/doi.org\/10.1074\/jbc.M207050200.","journal-title":"J Biol Chem"},{"issue":"6","key":"2055_CR59","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000088183","volume":"39","author":"M Matsumoto","year":"2005","unstructured":"Matsumoto M, Tsuji M, Sasaki H, Fujita K, Nomura R, Nakano K, et al. Cariogenicity of the probiotic bacterium lactobacillus salivarius in rats. Caries Res. 2005;39(6):479\u201383. https:\/\/doi.org\/10.1159\/000088183.","journal-title":"Caries Res"},{"issue":"10","key":"2055_CR60","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.4161\/cbt.5.10.3296","volume":"5","author":"MS Geier","year":"2006","unstructured":"Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol Ther. 2006;5(10):1265\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"2055_CR61","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11938-003-0020-y","volume":"6","author":"MH Floch","year":"2003","unstructured":"Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr Treat Options Gastroenterol. 2003;6(4):283\u20138.","journal-title":"Curr Treat Options Gastroenterol"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-02055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12866-020-02055-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-02055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:45:40Z","timestamp":1670071540000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-020-02055-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2055"],"URL":"https:\/\/doi.org\/10.1186\/s12866-020-02055-4","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"19 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental animal procedures performed were approved by the Institutional Animal Care and Use Committee (IACUC, Approval number: 16\u20130043-C2A1) of Seoul National University Hospital, which was accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}